期刊
TARGETED ONCOLOGY
卷 13, 期 6, 页码 715-724出版社
SPRINGER
DOI: 10.1007/s11523-018-0605-y
关键词
-
类别
资金
- Pfizer Inc.
- internal Hellenic Cooperative Oncology Group (HeCOG) translational research grant [HE_R3/07]
- Hellenic Study Group for Metastatic Liver Disease grant
BackgroundThe prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments.ObjectivesT determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I) and estimate the 6-month progression-free survival (PFS) in patients treated with the T+G combination (phase II).Patients and MethodsEligible patients with histologically confirmed inoperable or metastatic pancreatic carcinoma (MPC) were entered into the trial. G was given bi-weekly and T weekly in a 4-week cycle. The first dose level was set at G 800mg/m(2) and T 10mg. G was escalated in increments of 200mg/m(2) and T in increments of 5mg until DLT was reached, and the recommended dose was used for the phase II part.ResultsThirty patients were enrolled in the phase I component at the pre-planned six dose levels; one bilirubin DLT of grade III occurred at the first dose level. The MTD was established as the approved doses of both drugs. Fifty-five patients were entered into the phase II component. Median relative dose intensities administered in the first cycle were 0.75 for T and 0.99 for G. Grade 3-4 hematological toxicities were recorded in 87.3% of patients. The most common non-hematological adverse events were metabolic disorders (81.8%) followed by gastrointestinal disorders (63.6%). Median PFS was 2.69months (95% CI 1.74-4.95) and median OS was 4.95months (95% CI 3.54-6.85), while the 6-month PFS rate was 30.9%.ConclusionsCombination of G and T is feasible in patients with locally advanced or MPC with manageable side effects, but lacks clinical efficacy.The study was registered in the Australian New Zealand Clinical Trials Registry (ACTRN12611000643976).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据